These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18149062)

  • 21. [Studies on the problem of suramin fixation with blood proteins].
    OTT H; SEEGER C
    Z Gesamte Exp Med; 1955; 125(5):455-68. PubMed ID: 13247996
    [No Abstract]   [Full Text] [Related]  

  • 22. Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain.
    Kudlacek O; Waldhoer M; Kassack MU; Nickel P; Salmi JI; Freissmuth M; Nanoff C
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):8-16. PubMed ID: 11862328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suramin: prototype of a new generation of antitumor compounds.
    La Rocca RV; Stein CA; Myers CE
    Cancer Cells; 1990 Apr; 2(4):106-15. PubMed ID: 2202382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein.
    Lindman H; Taube A; Bergh JC
    Anticancer Res; 1994; 14(2A):363-6. PubMed ID: 7912491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S; Wientjes MG; Walsh C; Au JL
    Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of terminal complement proteins in solution and modulation by suramin.
    Saez C; Thielens NM; Bjes ES; Esser AF
    Biochemistry; 1999 May; 38(21):6807-16. PubMed ID: 10346902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suramin is a novel activator of PP5 and biphasically modulates S100-activated PP5 activity.
    Yamaguchi F; Yamamura S; Shimamoto S; Tokumitsu H; Tokuda M; Kobayashi R
    Appl Biochem Biotechnol; 2014 Jan; 172(1):237-47. PubMed ID: 24068474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis.
    Koval A; Ahmed K; Katanaev VL
    Biochem J; 2016 Feb; 473(4):371-81. PubMed ID: 26604320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
    Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery.
    Nautiyal A; Patil KN; Muniyappa K
    J Antimicrob Chemother; 2014 Jul; 69(7):1834-43. PubMed ID: 24722837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to drug by different isolates Trypanosoma evansi in China.
    Zhou J; Shen J; Liao D; Zhou Y; Lin J
    Acta Trop; 2004 May; 90(3):271-5. PubMed ID: 15099814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further observations on the determination of suramin in whole blood and serum.
    DEWEY HM; WORMALL A
    Biochem J; 1948; 43(1):24-7. PubMed ID: 18889860
    [No Abstract]   [Full Text] [Related]  

  • 35. Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
    Sartor O; McLellan CA; Myers CE; Borner MM
    J Clin Invest; 1992 Dec; 90(6):2166-74. PubMed ID: 1281826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suramin sodium. CI 1003, Metaret, suramin, suramin hexasodium.
    Drugs R D; 1999 Dec; 2(6):431-5. PubMed ID: 10763460
    [No Abstract]   [Full Text] [Related]  

  • 37. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
    Xin Y; Lyness G; Chen D; Song S; Wientjes MG; Au JL
    J Urol; 2005 Jul; 174(1):322-7. PubMed ID: 15947683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
    Hohenegger M; Matyash M; Poussu K; Herrmann-Frank A; Sarközi S; Lehmann-Horn F; Freissmuth M
    Mol Pharmacol; 1996 Dec; 50(6):1443-53. PubMed ID: 8967964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
    J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opposing effects of suramin and DL-alpha-difluoromethylornithine on polyamine metabolism contribute to a synergistic action on B16 melanoma cell growth in vitro.
    Gritli-Linde A; Björkman U; Delle U; Hultborn R; Johansson BR; Nannmark U; Linde A
    Anticancer Res; 1998; 18(2A):863-70. PubMed ID: 9615733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.